厄洛替尼在晚期非小细胞肺癌二线和三线治疗疗效比较(3)
[5] EisenhauerEA，Therasseb P，Bogaertsc J，et al. New respongse evaluation criteria in solid tumours：revised RECIST guideline(version 1.1)[J]. Eur J Cancer，2009,45(2)：228-247.
[6] Trotti A，Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials[J]. J Clin Oncol，2004，22(1)：19-22.
[7] Shepherd FA， Rodrigues PJ，Ciuleanu T，et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med，2005，353(2)：123-132.
[8] Ciuleanu T， Stelmakh L， Cicenas S， et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced，non-small-cell lung cancer with poor prognosis(TITAN)：a randomised multicentre，open-label，phase 3 study[J]. Lancet Oncol，2012，13(3)：300-308.
[9] Aoki T，Igawa S，Furuya N，et al. Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer[J]. Anticancer Res，2012，32(2)：601-608.
[10] 宋正波，虞永峰，陈智伟，等. 晚期非小细胞肺癌吉非替尼二线和三线治疗的疗效比较[J]. 肿瘤，2011，31(1)：53-57.
(收稿日期：2012-08-14), 百拇医药(林宝钗 邵岚 张贝贝 何春晓 郑蕾 洪卫 娄广媛 张沂平)
[6] Trotti A，Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials[J]. J Clin Oncol，2004，22(1)：19-22.
[7] Shepherd FA， Rodrigues PJ，Ciuleanu T，et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med，2005，353(2)：123-132.
[8] Ciuleanu T， Stelmakh L， Cicenas S， et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced，non-small-cell lung cancer with poor prognosis(TITAN)：a randomised multicentre，open-label，phase 3 study[J]. Lancet Oncol，2012，13(3)：300-308.
[9] Aoki T，Igawa S，Furuya N，et al. Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer[J]. Anticancer Res，2012，32(2)：601-608.
[10] 宋正波，虞永峰，陈智伟，等. 晚期非小细胞肺癌吉非替尼二线和三线治疗的疗效比较[J]. 肿瘤，2011，31(1)：53-57.
(收稿日期：2012-08-14), 百拇医药(林宝钗 邵岚 张贝贝 何春晓 郑蕾 洪卫 娄广媛 张沂平)